1. The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis
- Author
-
Shinobu Thanabashi, Susumu Imai, Junko Shiroko, Hiroyuki Sato, Kimihiro Yamaguchi, Mitsuru Okuno, Jun Takada, and Daisuke Taguchi
- Subjects
Male ,medicine.medical_specialty ,Diclofenac ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Administration, Rectal ,Risk Factors ,Internal medicine ,Internal Medicine ,medicine ,Odds Ratio ,Humans ,Risk factor ,Aged ,Retrospective Studies ,Aged, 80 and over ,Cholangiopancreatography, Endoscopic Retrograde ,Endoscopic retrograde cholangiopancreatography ,medicine.diagnostic_test ,business.industry ,Low dose ,Anti-Inflammatory Agents, Non-Steroidal ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,stomatognathic diseases ,Pancreatitis ,030220 oncology & carcinogenesis ,Rectal administration ,030211 gastroenterology & hepatology ,Female ,business ,medicine.drug - Abstract
Objective A 50-100-mg rectal dose of nonsteroidal anti-inflammatory drugs (NSAIDs; diclofenac or indomethacin) has been shown to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). However, this is higher than the recommended 25-mg dose that is commonly administered to Japanese patients. The objective of this study was to evaluate the safety and efficacy of 25-mg rectal dose of diclofenac in preventing PEP. Methods Between January 2016 and March 2017, a total of 147 patients underwent ERCP with or without the rectal administration of diclofenac (25 mg) 20 min before the procedure. A retrospective analysis was conducted to evaluate the efficacy and safety of this dose in preventing PEP. Results Thirteen patients (8.8%) developed PEP: 3 patients (4.1%) in the diclofenac group and 10 (13.7%) in the control group (p=0.0460). After ERCP, there were no cases of gastrointestinal hemorrhage, ulceration, acute renal failure, or death. A multivariate logistic regression analysis revealed that the non-administration of rectal diclofenac was a risk factor for PEP (odds ratio=3.530; 95% confidence interval=1.017-16.35; p=0.0468). Conclusions A 25-mg rectal dose of diclofenac might prevent PEP.
- Published
- 2018